戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ischemic-hemorrhagic transformation and/or a microangiopathic basis for the association of ischemic l
2         As part of the ancillary Genetics of Microangiopathic Brain Injury (GMBI) study, a neurocogni
3                              We investigated microangiopathic changes in the cerebellum of 16 genetic
4 e classified as confirmed (diarrhea, anemia, microangiopathic changes, low platelet count, and acute
5 ing and atherogenesis in diabetes and to the microangiopathic complications of the disease.
6 at causes hemolytic uremic syndrome (HUS), a microangiopathic disease characterized by hemolytic anem
7 rombotic thrombocytopenic purpura (TTP) is a microangiopathic disorder diagnosed by thrombocytopenia
8 ated in the pathogenesis of the catastrophic microangiopathic disorder, thrombotic thrombocytopenic p
9 will be made on the prototypes of thrombotic microangiopathic disorders, resulting from complement or
10 insights into the pathogenesis of thrombotic microangiopathic disorders.
11 asis for future classification of thrombotic microangiopathic disorders.
12      The failing grafts exhibited thrombotic microangiopathic glomerulopathy with multiple platelet-f
13 ient graft dysfunction with reversible, mild microangiopathic glomerulopathy, probably associated wit
14 ssociated with the development of thrombotic microangiopathic glomerulopathy.
15 ed that Gimap6-/- mice died prematurely from microangiopathic glomerulosclerosis most likely due to G
16 lly characterised by the triad of non-immune microangiopathic haemolytic anaemia, thrombocytopenia, a
17 ndrome characterized by thrombocytopenia and microangiopathic haemolytic anaemia, was almost universa
18 ity, which was followed by resolution of the microangiopathic hemolysis and improvement of the graft
19 gnificant protection from the development of microangiopathic hemolysis and renal insufficiency.
20 rovasculature resulting in thrombocytopenia, microangiopathic hemolysis, and organ dysfunction.
21  are both characterized by thrombocytopenia, microangiopathic hemolysis, and organ dysfunction.
22                         TMAs manifest with a microangiopathic hemolytic anaemia, thrombocytopenia, an
23 hrombotic microangiopathy that presents with microangiopathic hemolytic anemia (MAHA) and thrombocyto
24                                              Microangiopathic hemolytic anemia (MAHA) with thrombocyt
25 TP) is characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) without an obvi
26 pathophysiological pathways that can lead to microangiopathic hemolytic anemia and a procoagulant sta
27                Profound thrombocytopenia and microangiopathic hemolytic anemia characterize thromboti
28 ated with hemolytic uremic syndrome (HUS), a microangiopathic hemolytic anemia characterized by throm
29                  The infant displayed severe microangiopathic hemolytic anemia with renal involvement
30 drome (HUS), a disorder of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failu
31  with the clinical features of hypertension, microangiopathic hemolytic anemia, and acute renal failu
32 ndrome characterized by acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia
33  disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, mental status changes
34 ay also be associated with thrombocytopenia, microangiopathic hemolytic anemia, neurologic symptoms,
35 cell injury of various origins, resulting in microangiopathic hemolytic anemia, platelet consumption,
36  thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopen
37 odes of small-vessel thrombosis resulting in microangiopathic hemolytic anemia, thrombocytopenia and
38                                              Microangiopathic hemolytic anemia, thrombocytopenia, and
39      Hemolytic uremic syndrome is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and
40 emolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and
41  rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and
42 tic microangiopathy that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and
43                      TMA is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and
44 me (aHUS), a rare condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and
45 ment at the cell surface level that leads to microangiopathic hemolytic anemia, thrombocytopenia, and
46 ura (TTP) is the common name for adults with microangiopathic hemolytic anemia, thrombocytopenia, wit
47  the common features of thrombocytopenia and microangiopathic hemolytic anemia.
48 unction deteriorates, even in the absence of microangiopathic hemolytic anemia.
49 ects might have an impact on the severity of microangiopathic lesions after exposure to Stx-producing
50                            This inflammatory microangiopathic process is independently associated wit
51  linked to HIV infection includes thrombotic microangiopathic renal diseases, immune-mediated glomeru
52  of a thrombotic thrombocytopenic (TTP)-like microangiopathic state, that persisted longer when PCTx
53 er transplantation is idiopathic, thrombotic microangiopathic syndromes and nephrotic syndrome have b